Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ECG Exercise Stress Test in Coronary Artery Disease
Author(s): Gaetano Antonio Lanza Added: 9 months ago

Guidelines & Statements
Management of Left Main Coronary Artery Disease
Author(s): Gabriel Torres-Ruiz , Nuria Mallofré-Vila , Paola Rojas-Flores , et al Added: 2 years ago

Intervention

Prevention & Chronic Conditions
Left Main Disease: The Last Frontier for Medical Therapy in Stable CAD?
Author(s): Armin Arbab-Zadeh , Michelle Graham , Hector M Garcia-Garcia , et al Added: 6 months ago

Intervention

Prevention & Chronic Conditions
2024 ESC Guidelines on Peripheral Arterial and Aortic Diseases
Author(s): Giuseppe Ferrante , Brittany A Bacallao , Francesco Gioia , et al Added: 1 year ago

Vascular Disease and Surgery
Dual-pathway Inhibition versus Aspirin Monotherapy
Author(s): Dirk Sibbing , Michael J Blaha , Rajinder Chawla , et al Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more

Anticoagulation

Electrophysiology & Arrhythmia
The Hybrid Approach in CAD with Restore® DEB
Author(s): Alfonso Ielasi Added: 1 year ago
In this comprehensive video series, Dr Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant'Ambrogio, IT) delves into the approach of using Restore® Drug-Eluting Balloon (DEB) in treating Coronary Artery Disease (CAD). View more

Intervention
ACC 25: The EKSTROM Trial
Author(s): Matthew J Budoff Added: 11 months ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more

Intervention
Plaque Burden on CCTA Predicts MACE in Early CAD
Added: 1 week ago Source:  Radcliffe Vascular
A post hoc analysis of the PROMISE trial has found that quantitative coronary plaque measures derived from coronary computed tomographic angiography (CCTA) can independently predict major adverse cardiovascular events (MACE) in symptomatic patients without a known history of coronary artery disease (CAD).¹ The findings suggest that total plaque burden and noncalcified plaque burden may enhance… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
Non-invasive Coronary Functional Tests in ANOCA
Author(s): Nello Cambise , Angelo Giuseppe Marino , Fabio De Benedetto , et al Added: 1 month ago

Imaging & Diagnostics

Prevention & Chronic Conditions